Free tool
FAERS Monitor: Adasuve
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022549 or its brand name (Adasuve, Loxapine). Reports on generic versions are filed under their own applications.
Reports
3,993
Serious
3,781
95% of reports
Hospitalization
2,117
Death reported
626
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective322
- coma274
- somnolence262
- toxicity to various agents233
- drug interaction225
- weight increased219
- poisoning deliberate215
- off label use202
- suicide attempt185
- akathisia166
- death163
- neuroleptic malignant syndrome159
- drug abuse154
- product use in unapproved indication150
- tachycardia143
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 12 |
| 2005 | 13 |
| 2006 | 27 |
| 2007 | 26 |
| 2008 | 26 |
| 2009 | 20 |
| 2010 | 39 |
| 2011 | 54 |
| 2012 | 41 |
| 2013 | 35 |
| 2014 | 42 |
| 2015 | 81 |
| 2016 | 80 |
| 2017 | 132 |
| 2018 | 168 |
| 2019 | 232 |
| 2020 | 231 |
| 2021 | 276 |
| 2022 | 480 |
| 2023 | 530 |
| 2024 | 577 |
| 2025 | 483 |
| 2026 | 388 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,166 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| poisoning deliberateSignal | 215 | 122.2 | 107.1 | 25,153 |
| neuroleptic malignant syndromeSignal | 159 | 71.6 | 61.4 | 10,851 |
| akathisiaSignal | 166 | 64.9 | 55.8 | 10,254 |
| comaSignal | 274 | 30.5 | 27.2 | 7,756 |
| suicide attemptSignal | 185 | 16.1 | 14.0 | 2,608 |
| drug abuseSignal | 154 | 9.8 | 8.4 | 1,205 |
| tachycardiaSignal | 143 | 8.5 | 7.2 | 940 |
| drug interactionSignal | 225 | 7.5 | 6.6 | 1,264 |
| toxicity to various agentsSignal | 233 | 7.3 | 6.4 | 1,266 |
| somnolenceSignal | 262 | 6.9 | 6.1 | 1,317 |
| weight increasedSignal | 219 | 5.2 | 4.5 | 736 |
| product use in unapproved indicationSignal | 150 | 3.2 | 2.7 | 226 |
| drug ineffective | 322 | 1.3 | 1.2 | 22 |
| off label use | 202 | 1.2 | 1.1 | 8 |
| death | 163 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.